Observational studyTranslational stroke research2025
Serum Metabolome Profiling Reveals Biomarkers to Predict Malignant Brain Edema Following Endovascular Stroke Therapy.
Observational study in Translational stroke research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Metabolomics reflects the body's metabolic state and holds substantial promise for identifying associated biomarkers and exploring pathological processes. This study used serum metabolomics to predict malignant brain edema (MBE) following endovascular therapy (EVT) for acute ischemic stroke (AIS) and investigate the underlying mechanisms. In this prospective observational study, we enrolled patients with anterior circulation large vessel occlusion who underwent successful recanalization post-EVT for AIS, including those with or without concomitant hemorrhagic transformation. Eligible patients were stratified into two groups according to the subsequent presence of MBE. Following propensity score matching to adjust for potential confounders, widely targeted metabolomic analysis was conducted on the serum samples. A prediction model, based on the identified differential metabolites, was then developed and validated in another independent cohort. Through widely targeted metabolomic analysis of serum samples from matched 46 patients, we identified 30 metabolites that were significantly altered between patients with and without MBE, including notable differences in acylcarnitine, lysophosphatidylcholine, riboflavin, and tyrosine. A prediction model incorporating 9 differential metabolites was constructed using 10-fold frame shift cross-validation, demonstrating prediction performance in the training set, test set, and external validation, with areas under the curve (AUC) of 0.842, 0.815, and 0.734, respectively. Dynamic change analysis based on multiple time points may suggest a potential role of diminished oxidative energy supply and sustained stress in MBE. The identified acylcarnitine and lysophosphatidylcholine might play influential roles in the pathogenesis of MBE. The prediction model derived from these differential metabolites holds promise as a noninvasive assay for the early detection of MBE and warrants additional refinement and validation.
Indexed as
Identifiers
40748512What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.